Mr. Meister is co-founder of Liberty Lane Partners, LLC, a private investment company with investments in healthcare, technology, and distribution-related industries and Perspecta Trust, a trust company that provides trust and investment services.

Mr. Meister recently served as President of MacAndrews & Forbes Incorporated. He previously served as Chairman and CEO of inVentiv Health (now Syneos Health), a leading provider of commercial, consulting and clinical research services to the pharmaceutical and biotech industries.

Previously, Mr. Meister served as Chairman of the Board of Thermo Fisher Scientific, Inc. and Vice Chairman of Fisher Scientific International, Inc. prior to Fisher’s merger with Thermo.

During Mr. Meister’s tenure as an executive officer of Fisher Scientific, from 1991 to 2006, the company’s revenue and operating income grew at a compound annual growth rate of 15% and 23% respectively as operations grew from two countries to 27 and sales expanded into 140 countries worldwide.

Earlier in his career, Mr. Meister served in a number of executive leadership positions at Wheelabrator Technologies Inc., The Henley Group Inc., and AlliedSignal Inc. (now Honeywell International, Inc.). He began his career with Ford Motor Company.

Mr. Meister holds a Bachelor of Arts degree from the University of Michigan and an MBA from Northwestern University. He is a director of Aptiv PLC, Scientific Games Corporation, Quanterix Corporation; co-chair of the University of Michigan’s Life Sciences Institute External Advisory Board, chair of the Provost Advisory Board and serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University.

Ron Lowy serves on the boards and as an advisor to multiple medical device, education and information technology companies.

Mr. Lowy is currently the Executive Chairman of PharmaJet, Inc, a Needle-Free injection technology company. He also serves as Chairman of FluoroFinder, a developer and provider of cloud-based medical research tools and Chairman of the Advisory Board of Phase Holographic imaging, a provider of non-invasive cell imaging technology.

Mr. Lowy previously served as the President and CEO of the Biosciences division of Thermo Fisher Scientific, Inc. Prior to that he was President of Global Connectivity Solutions for ADC Telecommunications. He also served as President and Chief Operating Officer at the KRONE Group.

Mr. Lowy spent the first 15 years of his career in operations, technology and general management positions at GE Healthcare where he was active in GE’s development of Computerized Tomography (CT), Magnetic Resonance (MR) and multiple imaging technologies.

Mr. Lowy holds a Bachelor of Science degree in Mechanical Engineering from the University of New Hampshire and an MBA from the University of Wisconsin.

Greg Bullington, co-founder and Chief Executive Officer of Magnolia Medical Technologies, has led all commercial aspects of company development since inception including clinical trial design and execution, peer-reviewed publication, product development, manufacturing, commercial launch and overall intellectual property strategy. To date, Greg has raised over $30 million in capital to drive the successful growth and development of the company.

Greg has extensive experience in the healthcare industry having led product commercialization and strategy engagements for a wide variety of companies in the biotech (novel immunotherapy), healthcare insurance, wellness and enterprise software sectors.

Greg began his career in professional services with the Audit & Assurance practice of Deloitte & Touche LLP. He continued his professional development as a management consultant with Lake Partners, a Seattle-based strategy firm. In 2006, Greg founded Forum Ventures, a technology commercialization consultancy focused on accelerating the growth of early and mid-stage technology companies.

Over the past 15 years, Greg has led engagements and worked with senior executive teams at over 50 companies ranging from Fortune 100 corporations to venture-backed and early stage startups as a consultant, advisor, and investor. Additionally, Greg has significant intellectual property expertise and is the first named inventor on 28 issued patents as well as over 50 pending US and international patent applications.

Dr. Richard Patton, co-founder and Medical Director, is a board-certified pathologist with more than 40 years of active practice experience. Recognizing the patient safety and financial implications of false positive blood cultures, he has long been interested in exploring opportunities to reduce contamination rates.

In 2006, Dr. Patton designed a clinical trial to test the effectiveness of Initial Specimen Diversion Technique (ISDT), an innovation that he conceived earlier in his career. The results of the trial were significantly positive and published in the peer-reviewed Journal of Clinical Microbiology.

Dr. Patton’s areas of expertise are clinical microbiology, gastrointestinal pathology, and cytopathology. He was the Chief of Pathology and Medical Director of Clinical Laboratories at Northwest Hospital, Seattle, Washington for four decades. He has served as a Laboratory Inspector, Washington State Commissioner, NW Regional Commissioner, and Accreditation and Complaints Committee Member for the College of American Pathologists Laboratory Accreditation Program.

Randy is a Partner and co-founder of HealthQuest Capital, a venture capital firm focused on growth investments into companies transforming the value of healthcare. Prior to moving into venture capital, Randy was a successful medtech entrepreneur for many years.

Randy’s industry successes include starting NovaMin Technology, Inc. leading it through financing, growth and eventual acquisition by GlaxoSmithKline; a turn-around of USBiomaterials Corp, leading bone-grafting products company from perennial money-loser to profitability (now known as NovaBone Products, LLC); and a member of the early management team at LensCrafters as it emerged from start-up to market leader. He spent the first half of his career in consumer products marketing, starting in brand management at Procter & Gamble in Cincinnati. He is a graduate of Georgia Tech.

At HealthQuest Randy currently serves on the Boards of Magnolia Medical Technology, Trice Medical, Vestagen Protective Technologies, and Springbuk and is Board observer at CareMetx.

Josh is a Venture Partner at Split Rock Partners, and also serves as a Venture Partner at SightLine Partners. He has been with Split Rock since 2004 and with SightLine since 2014. Mr. Baltzell has over 20 years of experience in the healthcare industry.

Prior to his tenure in the venture capital industry, Josh held roles as an investment banker at Piper Jaffray Companies from 2000 to 2002, where he focused primarily on mergers and acquisitions in the medical device sector as well as various marketing and business development positions with SCIMED and Boston Scientific. Josh currently serves on the boards of Colorescience, EBR Systems, Inc., Entellus Medical (NASDAQ: ENTL), Histogenics Corporation (NASDAQ: HSGX) and Nanocyte Medical. Josh is also a co-inventor of the DentaDish.

Josh’s previous investments and board affiliations have resulted in several M&A transactions including Ardian (Medtronic), Dfine (Merit Medical), RF Surgical (Medtronic), Skinmedica (Allergan) and Tarsus (Integra Lifesciences).

Josh holds a B.A. in Economics from St. Olaf College and an M.B.A. from the University of Minnesota’s Carlson School of Management.

Paul Enever is a managing director at Canepa Healthcare. Before joining Canepa, Paul was a partner at McKinsey and Company. In his 12 years at McKinsey, he advised leading organizations across the bio-pharma, med-tech, hospital, and healthcare services industries primarily in the U.S. and Europe as well as private equity firms specializing in healthcare. Paul’s work focused on growth strategy, sales and marketing, and licensing and acquisition. Previously, Paul worked within the R&D organization at Sandoz Pharmaceuticals and MIT’s Biotechnology Process Engineering Center.

He sits on the Boards of Directors of Cardiva Medical, Dune Medical Devices, and Magnolia Medical Technologies.

Paul has a B.S. in chemical engineering from Rensselaer Polytechnic Institute and a Ph.D. in chemical engineering from the University of Minnesota where he studied wound healing and tissue engineering. For his work, Paul was the recipient of both a National Science Foundation Graduate Fellowship and the Whitaker Foundation Graduate Fellowship in Biomedical Engineering.

Garheng Kong is the founder and managing partner of HealthQuest Capital. He has over two decades of experience in the healthcare field as an investor, physician, scientist, and engineer.

Dr. Kong’s investments and board directorships have resulted in the IPOs of Cempra (CEMP), Alimera (ALIM), Applied Genetic Technology Corp. (AGTC), Proteon (PRTO), Histogenics (HSGX) and TransEnterix (TRXC). He has also had board roles in many M&A transactions that include Calibra Medical (J&J), Cellective (AstraZeneca), Serenex (Pfizer), Athenix (Bayer), NovaMin (GSK), Aldagen (Cytomedix), Salveo Specialty Pharmacy (Catamaran) and SARCode (Shire). Dr. Kong has been asked to Chair the board of seven companies as well.

Dr. Kong is a member of the board of directors of Laboratory Corporation of America (LabCorp, NYSE:LH) and Duke University Medical Center as well as Alimera Sciences (ALIM), Castle Biosciences, Cempra (CEMP), First Aid Shot Therapy, Histogenics (HSGX), Strongbridge (SBBP), Trice Medical and VirMedica. Dr. Kong’s interests and industry footprint are broad as he also serves on the board of SEBIO, Corporate Chaplains of America, Cure Network Ventures, and advises IDEO Palo Alto and numerous industry groups. He has also served on the Duke Medical Center Institutional Review Board (IRB) and as faculty at the Duke Fuqua School of Business as a senior scholar.

Dr. Kong received two undergraduate degrees, in chemical engineering and biological sciences, from Stanford University, which he attended on an athletic scholarship. He then earned his MD, PhD and MBA from Duke University, graduating at the top of his class in each instance. His early career included stints at GlaxoSmithKline, McKinsey & Co. and medical device startup TherOx. Dr. Kong has been founder and CEO of two successful biopharma companies (Cellective and Viamet). Prior to HealthQuest, he was a general partner at Intersouth Partners and a general partner at Sofinnova Ventures.